0
Summaries for Patients |

The Efficacy of the Drug Epoprostenol in the Treatment of Pulmonary Hypertension Associated with Scleroderma FREE

[+] Article and Author Information

The summary below is from the full report titled “Continuous Intravenous Epoprostenol for Pulmonary Hypertension Due to the Scleroderma Spectrum of Disease. A Randomized, Controlled Trial.”. It is in the 21 March 2000 issue of Annals of Internal Medicine (volume 132, pages 425-433). The authors are D.B. Badesch, V.F. Tapson, M.D. McGoon, B.H. Brundage, L.J. Rubin, F.M. Wigley, S. Rich, R.J. Barst, P.S. Barrett, K.M. Kral, M.M. Jöbsis, J.E. Loyd, S. Murali, A. Frost, R. Girgis, R.C. Bourge, D.D. Ralph, C.G. Elliott, N.S. Hill, D. Langleben, R.J. Schilz, V.V. McLaughlin, I.M. Robbins, B.M. Groves, S. Shapiro, T.A. Medsger Jr., S.P. Gaine, E. Horn, J.C. Decker, and K. Knob.


Ann Intern Med. 2000;132(6):425. doi:10.7326/0003-4819-132-6-200003210-00027
Text Size: A A A

What is the problem and what is known about it so far?

Pulmonary hypertension (high blood pressure in the arteries that go to the lungs) can produce disabling shortness of breath and often causes death. It can occur on its own (primary pulmonary hypertension) but is usually the result of an underlying lung disease, such as scleroderma (secondary pulmonary hypertension). No proven therapies for pulmonary hypertension are known, but epoprostenol, a drug that can dilate narrowed arteries, has shown promise in the treatment of patients with primary pulmonary hypertension.

Why did the researchers do this particular study?

The researchers wanted to see if epoprostenol would be useful in treating pulmonary hypertension that is secondary to scleroderma.

Who was studied?

One hundred eleven patients from 17 pulmonary hypertension centers in the United States with pulmonary hypertension associated with scleroderma.

How was the study done?

The researchers randomly assigned patients to receive either usual treatment or usual treatment plus epoprostenol. For 12 weeks, a pump delivered small amounts of epoprostenol continuously through a small tube inserted into a vein. The researchers measured the degree to which shortness of breath limited patients' activities by observing how far each patient could walk in 6 minutes, both at the beginning of the study and again after 1, 6, and 12 weeks of treatment.

hat did the researchers find?

The 56 patients who got epoprostenol increased the distance they could walk in 6 minutes from 270 to 316 meters. The 55 patients who received only usual therapy could walk 240 meters at the start of the study but only 192 meters at the end. Four epoprostenol patients and 5 usual therapy patients died during the course of the study. Frequent side effects of epoprostenol were jaw pain, diarrhea, nausea, and loss of appetite. Depression also occurred, but less commonly. In addition, patients who got epoprostenol had important side effects, including infection (4 patients) and bleeding (3 patients), that were related to the intravenous tube.

hat were the limitations of the study?

This study included too few patients to show whether epoprostenol improved survival among patients with scleroderma-associated pulmonary hypertension. Patients might find that the side effects and inconvenience of receiving epoprostenol continuously through an intravenous tube are not worth the improvement in exercise ability. It is also unclear whether the benefit observed in the 12 weeks of this study would continue over a longer period.

hat are the implications of the study?

Intravenous epoprostenol appears to improve exercise ability in patients with pulmonary hypertension due to scleroderma. However, associated side effects and the need for intravenous administration may limit the drug's usefulness.

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)